Clinical trials: Hepatic Tumors
Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma
Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
The objective of this pivotal study is to evaluate the safety and effectiveness of SIRT using SIR-Spheres Y-90 resin microspheres as first-line treatment for local control of HCC in patients with Barcelona Clinic Liver Cancer…
- Conditions
- Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
- Trial name
- DOORwaY90 (NCT04736121)
- Testing
- Resin microspheres containing yttrium-90 (Y-90)
- Where
- 22 sites in United States
- Volunteers
- 100 people
- Sponsor
- Sirtex Medical
Hepatocellular Carcinoma, Liver Cancer
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation…
- Trial name
- CheckMate 9DX (NCT03383458)
- Testing
- Nivolumab
- Where
- 184 sites in United States, Argentina and 23 more
- Volunteers
- 545 people
- Sponsor
- Bristol-Myers Squibb
Liver Ablation, Liver Cancer
A Retrospective Registry of Intelliblate DUAL Channel Microwave Ablation
This study reviews past patient records from multiple hospitals to learn how safe and effective the IntelliBlate Microwave Ablation System is when used to treat liver tumors with two probes at the same time.
- Conditions
- Liver Ablation, Liver Cancer, Liver Cancer (Primary and Metastatic)
- Trial name
- DUAL (NCT07900984)
- Testing
- Intelliblate Microwave Ablation (MWA) System
- Volunteers
- 63 people
- Sponsor
- Varian, a Siemens Healthineers Company
Advanced Hepatocellular Carcinoma, Inoperable Hepatocellular Carcinoma
A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
The purpose of this study is to determine whether AMG 386, in combination with Sorafenib, is effective in the treatment of advanced or inoperable Hepatocellular cancer in subjects who have not received any prior systemic therapy…
- Trial name
- NCT00872014
- Testing
- AMG 386, Sorafenib
- Volunteers
- 60 people
- Sponsor
- Amgen
Advanced Solid Tumor, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors
- Conditions
- Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04242199
- Testing
- INCB099280
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 182 people
- Sponsor
- Incyte Corporation
Hepatic Cancer
Seravue Validation Study for Hepatocellular Carcinoma (HCC) Diagnosis
Currently, ultrasound with or without AFP is the standard of care when it comes to surveillance for HCC in high-risk populations.
- Trial name
- Seravue (NCT06994130)
- Testing
- Seravue
- Where
- United States
- Volunteers
- 1,392 people
- Sponsor
- ImCare Biotech
Hepatic Encephalopathy
Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy
The primary purpose of this study is to evaluate the safety and effectiveness of Ammonul® in subjects who become hospitalized with Grade 3 or 4 hepatic encephalopathy (HE).
- Trial name
- NCT00597909
- Testing
- sodium phenylacetate and sodium benzoate injection 10% / 10%
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Amgen
Hepatic Impairment, Healthy Volunteers
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in healthy matched control participants with normal hepatic function.
- Trial name
- NCT06352528
- Testing
- Repotrectinib
- Where
- 3 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Esophagus Cancer, Hepatoma
Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
- Conditions
- Esophagus Cancer, Hepatoma, Glioma, Gastric Cancer
- Trial name
- NCT03941626
- Testing
- CAR-T/TCR-T cells immunotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shenzhen BinDeBio Ltd.
Liver Metastasis, Colorectal Neoplasms
Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases
The purpose of this study is to determine whether the Litx™ system is safe and effective in combination with chemotherapy in the treatment of liver metastasis arising from colorectal cancer.
- Conditions
- Liver Metastasis, Colorectal Neoplasms, Liver Neoplasms, Neoplasm Metastasis
- Trial name
- NCT00083785
- Testing
- Talaporfin sodium (LS11), LED-based light infusion device, Light emitting diodes (LED)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Light Sciences LLC
Hepatocellular Carcinoma
Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients
This is a single-arm, open-label and post-authorization study to evaluate the safety and efficacy profile of sorafenib and to evaluate Child-Pugh status progression in subjects with advanced HCC treated with sorafenib in Taiwan.
- Trial name
- HATT (NCT01098760)
- Testing
- Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment
- Where
- 7 sites in Taiwan
- Volunteers
- 151 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
Trial of TG4023 Combined With Flucytosine in Liver Tumors
This trial is a phase I, open-label, dose-escalating study of the safety or percutaneous intra-tumoral injection of TG4023 (MVA-FCU1) combined with systemic administration of 5-fluorocytosine in patients with primary or secondary…
- Trial name
- NCT00978107
- Testing
- MVA-FCU1, flucytosine
- Where
- 6 sites in France
- Volunteers
- 16 people
- Sponsor
- Transgene
Head and Neck Cancer, Lung Cancer
Clinical Evaluation of the New Hypoxia Imaging Agent HX4
Positron Emission Tomography (PET) with fluorine-18 fluoromisonidazole (FMISO) has been used for several years as a non invasive imaging technique to study tumor hypoxia.
- Conditions
- Head and Neck Cancer, Lung Cancer, Liver Cancer
- Trial name
- NCT01213030
- Testing
- [F-18] FMISO, [F-18] HX4
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Siemens Molecular Imaging
Hepatocellular Carcinoma
SynOV1.1 Intratumoral Injection Study
This is a Phase I, open-label, multicenter study to characterize safety and tolerability, evaluate biodistribution, biological effects and immunogenicity, and evaluate the preliminary clinical efficacy of SynOV1.1 in participants…
- Trial name
- NCT04612504
- Testing
- SynOV1.1
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Syngentech Co., Ltd.
Carcinoma, Hepatocellular
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
This open-label study will demonstrate proof-of-mechanism of HIF1A inhibition by a decrease of HIF1A mRNA after intravenous (IV) infusion of RO7070179 in participants with hepatocellular carcinoma (HCC) who have failed at least…
- Trial name
- NCT02564614
- Testing
- RO7070179
- Where
- 7 sites in United States
- Volunteers
- 9 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease.
- Trial name
- LIVIGNO-1 (NCT05822752)
- Testing
- Budigalimab, Livmoniplimab, Lenvatinib
- Where
- 59 sites in United States, France and 5 more
- Volunteers
- 130 people
- Sponsor
- AbbVie
Hepatocellular Carcinoma
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sorafenib.
- Trial name
- CELESTIAL (NCT01908426)
- Testing
- Cabozantinib tablets
- Where
- 104 sites in United States, Australia and 17 more
- Volunteers
- 707 people
- Sponsor
- Exelixis
Moderate Hepatic Impairment
Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants
The pharmacokinetics of a single dose of pexidartinib was investigated in participants with impaired hepatic function and compared with healthy control participants with normal hepatic function.
- Trial name
- NCT04223635
- Testing
- Pexidartinib
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
Ovarian Neoplasms, Neoplasms
Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients
Niraparib (Zejula®)is extensively metabolized and eliminated primarily by hepatic and renal pathways. The purpose of this study is to evaluate pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment…
- Conditions
- Ovarian Neoplasms, Neoplasms, Solid Tumor, Hepatic Impairment
- Trial name
- NCT03359850
- Testing
- Niraparib
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Tesaro, Inc.
Hepatocellular Carcinoma, HCC
GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma
This is a global phase II, open label study in the subjects with Advanced Hepatocellular Carcinoma (aHCC) who were intolerant or had progressed after or intolerant to first-line Immune Checkpoint Inhibitors (ICI) such as…
- Trial name
- NCT05178043
- Testing
- Nivolumab, GT90001
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,